Fish oil decreases C-reactive protein/albumin ratio improving nutritional prognosis and plasma fatty acid profile in colorectal cancer patients
Mocellin MC, Pastore e Silva Jde A, Camargo Cde Q, Fabre ME, Gevaerd S, Naliwaiko K, Moreno YM, Nunes EA, Trindade EB
Lipids · 76 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2013-07-25 · Lipids · vol. 48 · número 9 · págs. 879–888
- Editorial
- Wiley
- Citado
- 95 citas · más que el 95% de estudios similares · 5.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 48 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Inflammatory Biomarkers in Disease Prognosis · Clinical Nutrition and Gastroenterology
- Palabras clave
- fish oil supplementation, omega-3 fatty acids, colorectal cancer, C-reactive protein, C-reactive protein to albumin ratio, plasma fatty acid profile, eicosapentaenoic acid, docosahexaenoic acid, arachidonic acid, inflammatory cytokines, nutritional status
- MeSH
- animals, humans, colorectal neoplasms, docosahexaenoic acids, eicosapentaenoic acid, fatty acids, fish oils, tumor necrosis factor-alpha, c-reactive protein, serum albumin, interleukin-10, interleukin-17, body mass index, prognosis, treatment outcome, drug administration schedule, prospective studies, nutritional status, dietary supplements, adult, aged, middle aged, female, male, interleukin-1beta
9 autores
- Michel Carlos Mocellin🇧🇷 · autor de correspondenciaUniversidade Federal de Santa Catarina
- Juliana de Aguiar Pastore Silva
- Carolina de Quadros Camargo🇧🇷Universidade Federal de Santa Catarina
- Maria Emília de Souza Fabre
- Scheila Rosanne Gevaerd
- Katya Naliwaiko🇧🇷Universidade Federal do Paraná
- Yara María Franco Moreno🇧🇷Universidade Federal de Santa Catarina
- Everson Araújo Nunes🇧🇷Universidade Federal de Santa Catarina
- Erasmo Benício Santos de Moraes Trindade🇧🇷Universidade Federal de Santa Catarina
Resumen
El texto original del estudio, en el idioma en que se publicó.
Previous studies have shown that n-3 polyunsaturated fatty acids n-3 (n-3 PUFA) have several anticancer effects, especially attributed to their ability to modulate a variety of genomic and immune responses. In this context, this randomized, prospective, controlled clinical trial was conducted in order to check whether supplementation of 2 g/day of fish oil for 9 weeks alters the production of inflammatory markers, the plasma fatty acid profile and the nutritional status in patients with colorectal cancer (CRC). Eleven adults with CRC in chemotherapy were randomized into two groups: (a) supplemented (SG) daily with 2 g/day of encapsulated fish oil [providing 600 mg/day of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA)] for 9 weeks (n = 6), and (b) control (CG) (n = 5). All outcomes were evaluated on the day before the first chemotherapy session and 9 weeks later. Plasma TNF-α, IL-1β, IL-10 and IL-17A, the pro/anti-inflammatory balance (ratio TNF-α/IL-10 and IL-1β/IL10) and serum albumin, showed no significant changes between times and study groups (p > 0.05). C-reactive protein (CRP) and the CRP/albumin ratio showed opposite behavior in groups, significantly reducing their values in SG (p < 0.05). Plasma proportions of EPA and DHA increased 1.8 and 1.4 times, respectively, while the ARA reduced approximately 0.6 times with the supplementation (9 weeks vs baseline, p < 0.05). Patients from SG gained 1.2 kg (median) while the CG lost -0.5 kg (median) during the 9 weeks of chemotherapy (p = 0.72). These results demonstrate that 2 g/day of fish oil for 9 weeks of chemotherapy improves CRP values, CRP/albumin status, plasma fatty acid profile and potentially prevents weight loss during treatment.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.